AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01719172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veriset™ Hemostatic Patch
Description: Topical Hemostat
Study NCT03842605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Study NCT02185794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily
Study NCT02185794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match voxilaprevir
Description: Placebo to match voxilaprevir tablets administered orally once daily
Study NCT01900561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response Symptom Management
Description: The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.
Study NCT01900561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Newsletters
Description: Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
Study NCT00930163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab (MILR1444A)
Description: Subcutaneous repeating dose
Study NCT00930163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous repeating dose
Study NCT01510626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food proteins
Description: Food proteins
Study NCT01510626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Drug
Study NCT00709488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talaporfin sodium
Description: LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
Study NCT00709488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of device in prostate urethra
Description: Placement of device in prostate urethra
Study NCT00709488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transurethral illumination with light emitting diodes (Litx™ BPH Device)
Description: Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
Study NCT02826512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: niraparib 300 mg QD continuously
Study NCT03021863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A Reminder
Description: Tone of reminder email (duty 14 days followed by duty 28 days for non-responders)
Study NCT03021863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group B Reminder
Description: Tone of reminder email (encouragement 14 days followed by encouragement 28 days for non-responders)
Study NCT03021863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group C Reminder
Description: Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
Study NCT03021863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group D Reminder
Description: Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
Study NCT03021863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group E Reminder
Description: Tone of reminder email (generic reminders 14 days followed by 28 days for non-responders)
Study NCT03021863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group F Reminder
Description: Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
Study NCT03021863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group G Reminder
Description: Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
Study NCT03021863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group H Reminder
Description: Tone of reminder email ( duty14 days followed by generic for non-responders 28 days)
Study NCT03021863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group I Reminder
Description: Tone of reminder email (encouragement 14 days followed by generic non-responders 28 days)
Study NCT01667237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program
Description: The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
Study NCT02901548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.
Study NCT02901548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy with Biopsy
Description: Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
Study NCT00879411 — intervention group
Intervention type: DRUG
Intervention: Micardis
Study NCT04237935 — intervention group
Intervention type: DRUG
Intervention: Ticagrelor 90mg
Description: Ticagrelor 90 mg dispensing claim is used as the exposure group
Study NCT02939898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adjuvant therapy to recFSH during ovarian stimulation
Study NCT02939898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Adjuvant therapy to recFSH during ovarian stimulation
Study NCT02902640 — intervention group
Intervention type: DRUG
Intervention: Guaifenesin
Description: Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
Study NCT02132416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Will be used if tolerated.
Study NCT02132416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Initially intravenous administration and when tolerated oral slow-release pils will be used.
Study NCT02132416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural anaesthesia
Description: Given by specialists in anaesthesiology and intensive care.
Study NCT00367744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone 4mg BID
Study NCT00367744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rosiglitazone
Study NCT03664674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104
Description: Single intratympanic injection of 12 mg dexamethasone
Study NCT03664674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection of placebo
Study NCT03494517 — intervention group
Intervention type: DRUG
Intervention: Magnesium Sulfate
Description: Baseline EEG measurement will be performed for 5 minutes before intravenous magnesium administration will start as defined by the administration scheme of the Women's Hospital of the Bern University Hospital. After completion of the bolus infusion and at the beginning of the maintenance infusion of magnesium the second EEG measure will be performed for another 5 minutes. After 4 hours of intravenous magnesium treatment the plasmatic magnesium concentration is expected to be at a steady-state. A third 5-minute measure will be performed at this time point.
Study NCT04355533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serology test
Description: volume according to child weight
Study NCT04355533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swab
Description: nasopharyngeal swab for PCR
Study NCT04355533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rectal swab
Description: rectal swab for PCR
Study NCT04355533 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: for biocollection
Study NCT04213144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magdent Cap MED
Description: Magdent is intended to be used for accelaration of soft tissue and bone healing
Study NCT04213144 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MED
Description: Sham MED is intended to be used for soft tissue healing
Study NCT02868034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMT
Description: All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort.
Study NCT02868034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilizing Exercises
Description: Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
Study NCT02868034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activation Exercises
Description: Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
Study NCT02868034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMT extended
Description: This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
Study NCT02638207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam
Description: In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
Study NCT01025362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lactation counseling
Description: The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
Study NCT01025362 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Child Health Services offered standard care
Study NCT04237935 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75 mg dispensing claim is used as the reference group
Study NCT03629080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-101 vaccine
Description: HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
Study NCT02185794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400 mg/100 mg FDC tablet administered orally once daily
Study NCT02132416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1g QID will be given to all patients unless allergies.
Study NCT02132416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical management
Description: Fracture stabilization
Study NCT00252499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: PPAR-gamma agonist, insulin sensitizer
Study NCT01673594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SODAS MPH
Description: Adults with ADHD will receive open-label SODAS MPH
Study NCT02902640 — intervention group
Intervention type: DRUG
Intervention: Sulfamethoxazole
Description: Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
Study NCT01673594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SODAS MPH
Description: Adults with ADHD will receive open-label SODAS MPH
Study NCT02902640 — intervention group
Intervention type: DRUG
Intervention: Trimethoprim
Description: Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
Study NCT01182545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation
Description: Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
Study NCT01182545 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ventilation
Description: Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
Study NCT00765375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Neurotoxin Type A
Description: 1.5-3 units of Botox/lesion
Study NCT00765375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriostatic saline
Description: .1 cc bacteriostatic saline/lesion
Study NCT00237601 — intervention group
Intervention type: OTHER
Intervention: obstetric care
Study NCT02601950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
Study NCT01673594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Subjects randomized to the active double-blind group will receive Naltrexone HCl
Study NCT01711294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19 G Flex Needle
Description: Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
Study NCT03629080 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Saline will be used for placebo.
Study NCT01711294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 G Needle
Description: Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
Study NCT01711294 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19 G Needle
Description: Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
Study NCT02938377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Brief Intervention (CBI)
Description: A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.
Study NCT02938377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT4CBT
Description: 9 computerized modules delivered at the participant's pace
Study NCT03999788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar puncture and blood withdrawal
Description: lumbar puncture performed to detect OCB for diagnostic purposes and blood withdrawal for SNP screening
Study NCT03999788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity
Description: iTBS will be delivered over the scalp site corresponding to the leg area of primary motor cortex contralateral to the affected limb. The active motor threshold (AMT) will be defined as the minimum stimulation intensity required to evoke a liminal motor potential from the Soleus muscle during voluntary contraction. The stimulation intensity will be about 80% of AMT. The iTBS stimulation protocol consists of 10 bursts, each burst composed of three stimuli at 50 Hz, repeated at a theta frequency of 5 Hz every 10 s for a total of 600 stimuli (200 s). If no MEP will be detectable from the contralateral leg, the site of stimulation will be determined as symmetrical to the motor hot spot. If no MEP will be detectable even from the contralateral leg the coil will be held tangentially to the scalp with its centre placed 1 cm ahead and 1 cm lateral from CZ (10-20 EEG system). In these cases, stimulation intensity will be set to 50% of the maximum stimulator output.
Study NCT05825274 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cathodal tDCS
Description: We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
Study NCT02938377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recommendation and Counseling for Alcohol Pharmacotherapy
Description: The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
Study NCT05825274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Description: We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus
Study NCT02399319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Fixator
Description: Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
Study NCT02206867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LBAL
Description: Anti-inflammatory agents